Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oral supplement with an HA matrix ingredient composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%) to evaluate the hydration of the stratum corneum of facial skin in healthy women showing natural signs of age-related aging versus placebo

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

NCT06195605

Photoaging

RECRUITING NA

Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers

NCT01151436

Facial Wrinkles

COMPLETED NA

Study of Intradermal Injections of RCS-01 in Male and Female Subjects

NCT02391935

Intrinsic Aging of Skin Skin Wrinkling Solar Degeneration of Skin

COMPLETED PHASE1

Evaluation of the Anti-aging Efficacy of Two Dietary Supplements

NCT06032598

Healthy Volunteers

COMPLETED NA

Clinical and Biological Anti-aging Efficacy of a Cosmetic Cream

NCT05895591

Anti-aging

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study includes 60 healthy volunteers in which will be evaluated if the oral supplement with Dermial \[composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%)\] is able to obtain differences versus placebo in healthy women showing natural signs of age-related aging versus placebo . It is a single-center, double-blind, randomized, placebo-controlled clinical study with proportion 1:1 between treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HA matrix ingredient

1 cap/day

Group Type EXPERIMENTAL

HA matrix ingredient

Intervention Type DIETARY_SUPPLEMENT

1 capsule/day

Placebo

1 cap/day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

1 capsule/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HA matrix ingredient

1 capsule/day

Intervention Type DIETARY_SUPPLEMENT

Placebo

1 capsule/day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy women between 35 and 65 years of age (inclusive), showing signs of physiological facial skin aging.
2. Women willing not to use any firming product, skin lightening, or any other topical or systemic medication known to affect skin aging or dyschromia during the study period.
3. Be informed of the nature of the study and give their IC in writing.
4. Women willing not to become pregnant during the course of the study, using contraceptive methods considered highly effective.

Exclusion Criteria

1. Women with allergies to the ingredients in the investigational product.
2. Women who have used a dietary or nutricosmetic supplement containing HA, or who have undergone Botox or HA infiltrations, in the last 6 months prior to signing the IC.
3. Women who have undergone:

* Superficial or medium-deep chemical peels or dermabrasion within the 6 weeks prior to signing the IC or inclusion document.
* Deep facial chemical peel, non-ablative laser or fractional laser resurfacing in the 12 months prior to signing the IC or inclusion document.
* Facial plastic surgery or a laser ablative procedure for photoaging in the 12 months prior to signing the IC or inclusion document.
4. Suspected uncontrolled disease, such as diabetes mellitus (DM), arterial hypertension (HT), hyperthyroidism or hypothyroidism, renal failure or liver failure.
5. Women who have received a PRP (Platelet Rich Plasma) injection as a treatment for aesthetic purposes, in the 3 months prior to inclusion by signing the IC.
6. Women who do not wish, for whatever reason, to take the supplements in the study.
7. Known pregnancy or lactation.
8. Presence of inflammatory skin disease such as psoriasis, atopic dermatitis, rosacea, acne or hidradenitis suppurativa.
9. Presence of active malignant pathologies or premalignant skin lesions such as actinic keratoses.
10. Psychiatric disorder that is not managed or any other circumstance or pathology that prevents the participant from understanding and/or complying with the study procedures.

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes